<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223924</url>
  </required_header>
  <id_info>
    <org_study_id>PG-2008-1</org_study_id>
    <nct_id>NCT01223924</nct_id>
  </id_info>
  <brief_title>Single-dose Escalation Trial of M2ES in Healthy Volunteer</brief_title>
  <official_title>Randomized ，Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Protgen Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protgen Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blinded placebo-controlled，single-dose escalation trial in
      healthy volunteer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blinded placebo-controlled，single-dose escalation trial in health
      volunteer,to determine the safety and the max tolerate dose in health volunteer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine safety, toxicity and maxinum tolerable Dosage of M2ES injection in Safety and tolerability</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine safety, toxicity and maxinum tolerable Dosage of M2ES injection in Subjects With Advanced Solid Tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) behavior</measure>
    <time_frame>3 weeks</time_frame>
    <description>Pharmacokinetic (PK) behavior of two different doses in healthy volunteers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>M2ES 7.5-90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M2ES dose escalating</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo contract</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo conparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M2ES</intervention_name>
    <description>M2ES IV 7.5mg-90mg</description>
    <arm_group_label>M2ES 7.5-90mg</arm_group_label>
    <other_name>M2ES esculating</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Physical and mental healthy on the basis of a medical evaluation that reveals the
             absence of any clinically relevant abnormality and includes a physical examination,
             medical history, electrocardiogram (ECG), vital signs, and the results of blood
             biochemistry, blood coagulation and hematology tests and a urinalysis carried out at
             screening.

          2. 19 to 45 years of age.

          3. Body mass index (19-25 kg/m2) ,the body weight ≥55kg for male subject,≥45kg for
             female.

          4. Negative pregnant test, no menstrual period for female.

          5. willing to comply with the protocol.

        Exclusion Criteria:

          1. Be allergic to endostatin

          2. Have taken any drug during the last 2 weeks

          3. Have Participated any clinical trail during the last 2 week

          4. Cardiovasculre, respiratory, Liver, renal, gastro-intestinal hematologic endocrine and
             mental disease

          5. HIV-1 infected

          6. HBV, HBV infected ,Hepatitis B surface antigen positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji JIANG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Perking Union Medical College Hospital</affiliation>
  </overall_official>
  <verification_date>October 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>October 18, 2010</last_update_submitted>
  <last_update_submitted_qc>October 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Guodong Chang</name_title>
    <organization>Protgen Ltd</organization>
  </responsible_party>
  <keyword>cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

